Fralick M, et al. - In this population-based cohort study of 12,858 patients who filled a prescription for the medication from two commercial insurance databases, researchers examined dextromethorphan-quinidine prescription patterns, including trends in related costs, after it was approved by the US Food and Drug Administration’s (FDA) for pseudobulbar affect. Patients were eligible if they were prescribed dextromethorphan-quinidine from October 29, 2010, when the drug was approved, through March 1, 2017, for Optum Clinformatics Data Mart and December 31, 2015, for Truven Health MarketScan. According to findings, dextromethorphan-quinidine seems to be mainly prescribed for patients with dementia and/or Parkinson disease (PD), even with FDA approval for pseudobulbar affect based on studies of patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).